Neurodegenerative Diseases clinical trials
The registry lists 436 studies for Neurodegenerative Diseases across more than 10 countries. 143 are recruiting or about to start. 86 of them are mainly about Neurodegenerative Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 51 narrower conditions too, such as Parkinson Disease: 12,899 studies, 3,184 open.
Get an email when these change. Save the Neurodegenerative Diseases studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Drexel University College of Medicine (10) · Tammie L. S. Benzinger, MD, PhD (7) · Radboud University Medical Center (6) · GenSight Biologics (6) · AbbVie (5) · National Institute of Environmental Health Sciences (NIEHS) (5) · Eli Lilly and Company (5) · Novartis Pharmaceuticals (4)
What is being tested here
Drugs under test in Neurodegenerative Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| ML-007C | 2 | 0 | 2 |
| Donanemab | 1 | 1 | 2 |
| Riluzole | 1 | 0 | 1 |
| Inosine | 1 | 0 | 1 |
| Phytic Acid | 1 | 0 | 1 |
| Fosigotifator | 1 | 0 | 1 |
| Pimavanserin | 1 | 0 | 1 |
| Ambroxol | 1 | 1 | 1 |
| Tavapadon | 0 | 4 | 5 |
| Amilomotide | 0 | 0 | 5 |
Drug classes tested here Dopamine agonists 7 · Cholinesterase inhibitors 4
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Jul 2027A Phase 3 Study of NTLA-2001 in ATTRv-PN · Phase 3 · Intellia Therapeutics
- Nov 2026Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease · University of Arizona
- Dec 2026Construction of AI Model for Precision Imaging Diagnosis of Cranial Diseases · Tongji Hospital
- Dec 2026Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases · Novabio Therapeutics
- Dec 2026Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease · Bristol-Myers Squibb
- Dec 2026Study on the Application of ¹⁸F-FCOB04, a MAO-B Targeted PET Imaging Agent, in Neurodegenerative Diseases · Peking Union Medical College Hospital
- Jan 2027F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project) · Washington University School of Medicine
- Jan 2027Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia · Advanced Technology & Communications
- Jan 2027Functionalized Point of Care and 3D Printed Dental Aligners as Devices for Early Detection of Neurodegenerative Diseases · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Feb 2027Elemental 028 Extra Case Studies · Nutricia UK Ltd
Who these studies take
Of the 101 Neurodegenerative Diseases studies recruiting now, 52 (51%) set no upper age limit and 11 (11%) stop at 75 or younger. 20 (20%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 49 (49%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 19 (19%) | 19 (19%) |
| 18 | 59 (58%) | 58 (57%) |
| 30 | 69 (68%) | 68 (67%) |
| 40 | 77 (76%) | 76 (75%) |
| 50 | 88 (87%) | 87 (86%) |
| 65 | 97 (96%) | 96 (95%) |
| 75 | 93 (92%) | 92 (91%) |
| 85 | 73 (72%) | 72 (71%) |
Across all 436 studies, recruiting or not: 15% stop at 75 or younger and 5% at 65; 15% take children; 1% are for women only and <1% for men only; 32% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Neurodegenerative Diseases studies take
Of 35 phase 2 interventional studies under Neurodegenerative Diseases, half reached primary completion within 30 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 22 mo11–41 · 29 studies | — | — |
| Phase 2 | 30 mo22–47 · 35 studies | — | — |
| Phase 3 | 53 mo34–56 · 16 studies | — | — |
| Interventional, no phase | 35 mo11–67 · 82 studies | — | 35 mo10–57 · 75 studies |
| Observational | 94 mo39–216 · 82 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 11, 2026.
Newly registered5
- Development, Validation and Normative Data of the Italian Battery for the Recognition of Famous Faces (FAME)Nov 3, 2026NCT07911878
- Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence ModelsOct 30, 2026NCT07906769
- Register for Medical Data, Functional Scales, and Care Outcomes in ALS, SMA, and Other Motor System DisordersOct 28, 2026NCT07900672
- Clinical Cohort of Memory DisordersOct 19, 2026NCT07880275
- Functionalized Point of Care and 3D Printed Dental Aligners as Devices for Early Detection of Neurodegenerative DiseasesOct 13, 2026NCT07870070
Studies
Recruiting first, then most recently updated. Showing 50 of 436. Browse all 436 → or search them.
- A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic TherapyRecruitingNCT07804615Phase 22 countries
- Electroencephalogram in Patients With Friedreich's Ataxia for the Study of the Structural and Functional Connectome.RecruitingNCT07095062Not applicable1 country
- A Study of LY3439539 in Participants With Alzheimer's DiseaseRecruitingNCT07598370Phase 14 countries
- A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)RecruitingNCT07589595Phase 24 countries
- Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence ModelsRecruitingNCT07906769Not applicable1 country
- Development, Validation and Normative Data of the Italian Battery for the Recognition of Famous Faces (FAME)RecruitingNCT079118781 country
- A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's DiseaseRecruitingNCT06297590Phase 13 countries
- Register for Medical Data, Functional Scales, and Care Outcomes in ALS, SMA, and Other Motor System DisordersRecruitingNCT079006721 country
- Speech and Language Interventions for Italian People With PPARecruitingNCT067399671 country
- Clinical Cohort of Memory DisordersRecruitingNCT078802751 country
- An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter DiseaseRecruitingNCT05757141Phase 1/23 countries
- PET Tau - Neurodegenerative Disease ImagingRecruitingNCT03143374Phase 2/31 country
- A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's DiseaseRecruitingNCT06585449Phase 13 countries
- Slow-SPEED: Slowing Parkinson's Early Through Exercise DosageRecruitingNCT06993142Not applicable2 countries
- A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type IEnrolling by invitationNCT06926621Phase 28 countries
- Neurofilament Light Chain And Voice Acoustic Analyses In Dementia DiagnosisRecruitingNCT063391901 country
- A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisRecruitingNCT06887192Phase 215 countries
- The Neurodevelopmental and Behavioral Phenotyping Screening ProtocolRecruitingNCT002716221 country
- Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase InhibitorNot yet recruitingNCT07832383Phase 2
- Cognition and Affective Research in ChinaNot yet recruitingNCT078332671 country
- A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD)Not yet recruitingNCT07832370Phase 1/2
- Effects of Long Term Ventilation Support on the Quality of Life of ALS Patients and Their FamiliesRecruitingNCT05744310Not applicable1 country
- Neurodegenerative Diseases RegistryRecruitingNCT044721301 country
- Home Exercise for Individuals With Neurodegenerative DiseaseRecruitingNCT05443906Not applicable1 country
- Prenatal Education on Environmental Exposures During Pregnancy Study (PEEPS)RecruitingNCT07758114Not applicable1 country
- Observational Pharmaco-Epidemiology Research & AnalysisRecruitingNCT038138621 country
- Parkinson Progression Marker Initiative Online (PPMI Online)RecruitingNCT050650601 country
- Beta Amyloid PET/CT in Various Aβ-Related DiseaseRecruitingNCT067257061 country
- Human Observatory StudyRecruitingNCT076467821 country
- Translocator Protein PET/CT in Various TSPO-Related DiseaseRecruitingNCT067257191 country
- [18F]NIDF PET Imaging in Tau-related DiseasesRecruitingNCT073065981 country
- Tau PET/CT in Various Tau-Related Disease PatientsRecruitingNCT066909831 country
- Neurodegenerative Diseases Progression Markers (MARKERS-NDD)RecruitingNCT065967461 country
- Biofluid Research on Age-Related or Inherited NeurodegenerationRecruitingNCT077987001 country
- Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History StudyRecruitingNCT0601694617 countries
- Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-NetherlandsRecruitingNCT06193252Not applicable1 country
- rTMS as an Intervention for Levodopa-induced DyskinesiaRecruitingNCT06570824Not applicable1 country
- Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)RecruitingNCT06482268Phase 11 country
- Multimodal Assesment of Alzheimer PatientsRecruitingNCT064484031 country
- Memory Deterioration in Alzheimer DiseaseRecruitingNCT071181371 country
- Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative DiseasesRecruitingNCT05357612Phase 41 country
- An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease PsychosisEnrolling by invitationNCT07459660Phase 23 countries
- PPMI Clinical - Establishing a Deeply Phenotyped PD CohortRecruitingNCT0447778512 countries
- Optimization of Adaptive Rowing SeatingNot yet recruitingNCT07099625Not applicable1 country
- ZR001 Chemogenetics Gene Therapy Study in Patients With Parkinson's DiseaseNot yet recruitingNCT07718659Phase 11 country
- Serum Neurofilaments in the Diagnosis of Amyotrophic Lateral SclerosisNot yet recruitingNCT07706270
- Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease - EUNot yet recruitingNCT07708675Not applicable
- Imaging Studies in Corticobasal SyndromeRecruitingNCT070008511 country
- Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2Enrolling by invitationNCT058544331 country
- Analysis of Human ALS Tissues and Registry of ALS PatientsRecruitingNCT050671791 country